EU policies in personalized medicine-related technologies

Sibylle Gaisser, Etienne Vignola-Gagné, Bärbel Hüsing, Christien Enzing, Tessa van der Valk

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Against the background of a number of first drug-diagnostic co-products developed and introduce into the European market, European decision-makers feel impelled to react and position themselves in the field of personalized medicine. Their reactions cover a broad range, from the analysis of knowledge requirements for market approval to the need for translational activities and the possible contribution of pharmacogenetics to public health. This article summarizes the current positions of European institutions, based on literature review and expert consultation for three items associated with personalized medicine: biobanks, genetic diagnostics and drug-diagnostic co-products, and provides an outlook on requirements for an effective futute European policy on personalized medicine.

Original languageEnglish
Pages (from-to)93-102
Number of pages10
JournalPersonalized Medicine
Issue number1
StatePublished - 2009
Externally publishedYes


  • Biobanks
  • Clinical utility
  • Clinical validity
  • Drug-diagnostic co-development
  • Effectiveness
  • European policy
  • Framework conditions
  • Genetic diagnostics
  • Translational research


Dive into the research topics of 'EU policies in personalized medicine-related technologies'. Together they form a unique fingerprint.

Cite this